Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-82 with Everolimus in Pancreatic Neuroendocrine Tumors
NCT01784861Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- May 2013
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorolanib in Pancreatic neuroendocrine tumor (PanNET) (6 arms), sponsored by Washington University School of Medicine. Primary endpoints: Dose Limiting Toxicities, Overall Toxicities and 2 more. Started May 2013; status: terminated.
02
Drugs
vorolanib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01784861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01784861.